Acceleron Pharma, a clinical stage biotech developing protein therapeutics for cancer and rare diseases, filed on Wednesday with the SEC to raise up to $75 million in an initial public offering. The Cambridge, MA-based company, which was founded in 2003 and booked $27 million in collaboration revenue for the 12 months ended March 31, 2013, plans to list on the NASDAQ under the symbol XLRN. Acceleron Pharma initially filed confidentially on July 3, 2013. Citi and Leerink Swann are the joint bookrunners on the deal. No pricing terms were disclosed.
